The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1350
Desirudin (Iprivask) for DVT Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin, the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous thromboembolism (VTE) after elective hip arthroplasty, but was only marketed recently in the US. It has been available in Europe as Revasc for about 10 years. Two other hirudin analogs are available in the US: lepirudin (Refludan) for treatment of heparin-induced thrombocytopenia (HIT) and bivalirudin (Angiomax) for use in percutaneous coronary intervention (PCI).

DRUGS FOR VTE PREVENTION — Most patients undergoing elective hip arthroplasty in the US are treated parenterally with a low-molecular-weight heparin (LMWH) such as enoxaparin (Lovenox, and others) or fondaparinux (Arixtra), a synthetic analog of heparin, or orally with warfarin (Coumadin, and others). ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Desirudin (Iprivask) for DVT Prevention
Article code: 1350a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian